Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.

ABSTRACT:

Importance

Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD).

Objective

To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD.

Design, setting, and participants

The Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) study was a phase 2a randomized double-blinded placebo-controlled crossover clinical trial of 34 adults with AD that was conducted at the University of California, San Francisco, and the University of Minnesota, Twin Cities, between October 16, 2014, and July 21, 2020. Participants were adults 80 years and younger who had a Mini-Mental State Examination score of 18 points or higher and/or a Clinical Dementia Rating score

SUBMITTER: Vossel K 

PROVIDER: S-EPMC8477304 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature